Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term protection and immunogenicity of bivalent HPV 16/18 (E. coli) vaccine in adult women
CTR20231471Phase 4Active
- Sponsor
- Xiamen University
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of human papillomavirus bivalent vaccine (types 16, 18) in HPV16 infection (HPV16), human papillomavirus infection type 18, cervical intraepithelial neoplasia (CIN) and 5 more, sponsored by Xiamen University. Primary endpoint: HPV16/18-related CIN2+ and/or VIN2+ and/or VaIN2+ lesions. Started Mar 2021; status: active.
02
Drugs
human papillomavirus bivalent vaccine (types 16, 18)
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18cervical intraepithelial neoplasia (CIN)vulvar intraepithelial neoplasia (VIN)vaginal intraepithelial neoplasia (VAIN)
Beyond the preview
Go deeper on CTR20231471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231471.